Findings

What do systematic reviews say?

10 questions · 10 findings · 6 reviews · Pain, Palliative and Supportive Care

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 7 · 70%Low 1 · 10%Moderate 2 · 20%High 0 · 0%

Serious adverse events · adults with fibromyalgia enrolled in EERW studies

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 687 participants
Very low

Serious adverse events · adults with fibromyalgia

1 finding from 1 review

Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 1238 participants
Very low

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antiepileptic drugs for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 107 participants
Very low

Serious adverse events · patients with fibromyalgia

Pregabalin showed no clear difference in serious adverse events compared with placebo at end of treatment (moderate certainty).

1 finding from 1 review

Anticonvulsants for fibromyalgia 2013 · Cochrane Headline outcomes only
RR 1.03 [0.71, 1.49]
4 studies · 2729 participants
Moderate

Serious adverse events · adults with metastatic extradural spinal cord compression (without peptic ulceration or infection; mixed prognosis)

High‐dose corticosteroids probably leads to higher serious adverse events compared with moderate‐dose or no corticosteroids (moderate certainty).

1 finding from 1 review

Interventions for the treatment of metastatic extradural spinal cord compression in adults 2015 · Cochrane Headline outcomes only
RR 8.02 [1.03, 62.37]
2 studies · 77 participants
Moderate

Serious adverse events · cancer patients

Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).

1 finding from 1 review

Serious adverse events · cancer patients

It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).

1 finding from 1 review

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

Serious adverse events · children (4 to 18 years) with functional abdominal pain disorders

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 115 participants
Very low

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 34 participants
Very low